The stock of Kyverna Therapeutics Inc (NASDAQ: KYTX) has decreased by -9.77 when compared to last closing price of 3.07.Despite this, the company has seen a loss of -13.17% in its stock price over the last five trading days. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC acquired a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 11,488 shares of the company’s stock, valued at approximately $43,000. A number of other institutional investors have also made changes to their positions in KYTX. Corton Capital Inc. bought a new position in Kyverna Therapeutics in the 4th quarter worth approximately $45,000. Corebridge Financial Inc. increased its position in Kyverna Therapeutics by 42.3% in the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after buying an additional 3,810 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kyverna Therapeutics by 53.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company’s stock worth $53,000 after buying an additional 4,990 shares during the period. Bank of America Corp DE increased its position in Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares during the period. Finally, Rhumbline Advisers increased its position in Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock worth $97,000 after buying an additional 6,153 shares during the period. 18.08% of the stock is owned by institutional investors. Kyverna Therapeutics Price Performance Shares of Kyverna Therapeutics stock opened at $3.60 on Wednesday. The business has a fifty day simple moving average of $2.24 and a two-hundred day simple moving average of $3.01. Kyverna Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $16.64. The company has a market capitalization of $155.59 million, a price-to-earnings ratio of -1.07 and a beta of 2.52. Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.18. As a group, equities analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades KYTX has been the topic of a number of research reports. Morgan Stanley lowered their price objective on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 1st. HC Wainwright upgraded Kyverna Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $4.00 to $5.00 in a research report on Tuesday, May 27th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $18.50. View Our Latest Stock Analysis on Kyverna Therapeutics Kyverna Therapeutics Profile (Free Report) Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Is It Worth Investing in Kyverna Therapeutics Inc (NASDAQ: KYTX) Right Now?
The 36-month beta value for KYTX is at 2.97. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KYTX is 19.45M, and currently, shorts hold a 10.79% of that float. The average trading volume for KYTX on July 02, 2025 was 397.88K shares.
KYTX’s Market Performance
KYTX’s stock has seen a -13.17% decrease for the week, with a 8.63% rise in the past month and a 43.52% gain in the past quarter. The volatility ratio for the week is 12.80%, and the volatility levels for the past 30 days are at 10.93% for Kyverna Therapeutics Inc The simple moving average for the past 20 days is -12.30% for KYTX’s stock, with a -23.02% simple moving average for the past 200 days.
Analysts’ Opinion of KYTX
Many brokerage firms have already submitted their reports for KYTX stocks, with H.C. Wainwright repeating the rating for KYTX by listing it as a “Buy.” The predicted price for KYTX in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on May 27, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see KYTX reach a price target of $13. The rating they have provided for KYTX stocks is “Buy” according to the report published on October 10th, 2024.
Rodman & Renshaw gave a rating of “Buy” to KYTX, setting the target price at $16 in the report published on October 09th of the previous year.
KYTX Trading at 6.15% from the 50-Day Moving Average
After a stumble in the market that brought KYTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.70% of loss for the given period.
Stock Fundamentals for KYTX
The total capital return value is set at -0.71. Equity return is now at value -49.72, with -44.70 for asset returns.
Based on Kyverna Therapeutics Inc (KYTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -19.26. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -2200.74.
Currently, EBITDA for the company is -142.6 million with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.44.
Conclusion
In conclusion, Kyverna Therapeutics Inc (KYTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
